DOCSLIB.ORG

Restoring Study 329: Efficacy and Harms of Paroxetine and BMJ: First Published As 10.1136/Bmj.H4320 on 16 September 2015

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Restoring Study 329: Efficacy and Harms of Paroxetine and BMJ: First Published As 10.1136/Bmj.H4320 on 16 September 2015 RESEARCH OPEN ACCESS Restoring Study 329: efficacy and harms of paroxetine and BMJ: first published as 10.1136/bmj.h4320 on 16 September 2015. Downloaded from imipramine in treatment of major depression in adolescence Joanna Le Noury,1 John M Nardo,2 David Healy,1 Jon Jureidini,3 Melissa Raven,3 Catalin Tufanaru,4 Elia Abi-Jaoude5 1School of Medical Sciences, ABSTRACT (HAM-D score ≤8 or ≥50% reduction in baseline HAM-D) Bangor University, Bangor, OBJECTIVES at acute endpoint. Prespecified secondary outcomes Wales, UK To reanalyse SmithKline Beecham’s Study 329 were changes from baseline to endpoint in depression 2 Emory University, Atlanta, (published by Keller and colleagues in 2001), the items in K-SADS-L, clinical global impression, Georgia, USA primary objective of which was to compare the efficacy autonomous functioning checklist, self-perception 3Critical and Ethical Mental Health Research Group, and safety of paroxetine and imipramine with placebo profile, and sickness impact scale; predictors of Robinson Research Institute, in the treatment of adolescents with unipolar major response; and number of patients who relapse during University of Adelaide, depression. The reanalysis under the restoring invisible the maintenance phase. Adverse experiences were to Adelaide, South Australia, Australia and abandoned trials (RIAT) initiative was done to see be compared primarily by using descriptive statistics. 4Joanna Briggs Institute, Faculty whether access to and reanalysis of a full dataset from No coding dictionary was prespecified. of Health Sciences, University of a randomised controlled trial would have clinically RESULTS Adelaide, Adelaide, South relevant implications for evidence based medicine. Australia, Australia The efficacy of paroxetine and imipramine was not 5Department of Psychiatry, The DESIGN statistically or clinically significantly different from Hospital for Sick Children, Double blind randomised placebo controlled trial. placebo for any prespecified primary or secondary University of Toronto, Toronto, SETTING efficacy outcome. HAM-D scores decreased by 10.7 Ontario, Canada 12 North American academic psychiatry centres, from (least squares mean) (95% confidence interval 9.1 to Correspondence to: J Jureidini 12.3), 9.0 (7.4 to 10.5), and 9.1 (7.5 to 10.7) points, [email protected] 20 April 1994 to 15 February 1998. respectively, for the paroxetine, imipramine and Additional material is published PARTICIPANTS placebo groups (P=0.20). There were clinically online only. To view please visit 275 adolescents with major depression of at least the journal online (http://dx.doi. significant increases in harms, including suicidal eight weeks in duration. Exclusion criteria included a org/10.1136/bmj.h4320) ideation and behaviour and other serious adverse range of comorbid psychiatric and medical disorders Cite this as: BMJ 2015;351:h4320 events in the paroxetine group and cardiovascular doi: 10.1136/bmj.h4320 and suicidality. problems in the imipramine group. Accepted: 03 August 2015 INTERVENTIONS http://www.bmj.com/ CONCLUSIONS Participants were randomised to eight weeks double Neither paroxetine nor high dose imipramine showed blind treatment with paroxetine (20-40 mg), efficacy for major depression in adolescents, and there imipramine (200-300 mg), or placebo. was an increase in harms with both drugs. Access to MAIN OUTCOME MEASURES primary data from trials has important implications for The prespecified primary efficacy variables were both clinical practice and research, including that change from baseline to the end of the eight week published conclusions about efficacy and safety acute treatment phase in total Hamilton depression should not be read as authoritative. The reanalysis of on 2 October 2021 by guest. Protected copyright. scale (HAM-D) score and the proportion of responders Study 329 illustrates the necessity of making primary trial data and protocols available to increase the rigour of the evidence base. WHat IS ALREADY KNOWN ON THIS TOPIC There is a lack of access to data from most clinical randomised controlled trials, Introduction making it difficult to detect biased reporting In 2013, in the face of the selective reporting of outcomes In the absence of access to primary data, misleading conclusions in publications of of randomised controlled trials, an international group of those trials can seem definitive researchers called on funders and investigators of aban- SmithKline Beecham’s Study 329, an influential trial that reported that paroxetine doned (unpublished) or misreported trials to publish was safe and effective for adolescents, is one such study undisclosed outcomes or correct misleading publica- tions.1 This initiative was called “restoring invisible and WHat THIS stUDY ADDS abandoned trials” (RIAT). The researchers identified On the basis of access to the original data from Study 329, we report a reanalysis many trials requiring restoration and emailed the funders, that concludes that paroxetine was ineffective and unsafe in this study asking them to signal their intention to publish the unpub- Access to primary data makes clear the many ways in which data can be analysed lished trials or publish corrected versions of misreported and represented, showing the importance of access to data and the value of trials. If funders and investigators failed to undertake to reanalysis of trials correct a trial that had been identified as unpublished or misreported, independent groups were encouraged to There are important implications for clinical practice, research, regulation of trials, publish an accurate representation of the clinical trial licensing of drugs, and the sociology and philosophy of science based on the relevant regulatory information. Our reanalysis required development of methods that could be adapted for future The current article represents a RIAT publication reanalyses of randomised controlled trials of Study 329. The original study was funded by the bmj | BMJ 2015;101hh432 | doi1 10.00;6/bmj.h4320 1 RESEARCH SmithKline Beecham (SKB; subsequently GlaxoSmith- information on the safety profile of paroxetine and imip- BMJ: first published as 10.1136/bmj.h4320 on 16 September 2015. Downloaded from Kline, GSK). We acknowledge the work of the original ramine when these drugs were given for “an extended investigators. This double blinded randomised con- period of time”; and to estimate the rate of relapse among trolled trial to evaluate the efficacy and safety of parox- patients who responded to imipramine, paroxetine, and etine and imipramine compared with placebo for placebo and were maintained on treatment. Study enrol- adolescents diagnosed with major depression was ment took place between April 1994 and March 1997. reported in the Journal of the American Academy of The first RIAT trial publication was a surgery trial that Child and Adolescent Psychiatry (JAACAP) in 2001, with had been only partly published before.7 Few previously Martin Keller as the primary author.2 The RIAT published randomised controlled trials have ever been researchers identified Study 329 as an example of a subsequently reported in published papers by different misreported trial in need of restoration. The article by teams of authors.8 Keller and colleagues, which was largely ghostwritten,3 claimed efficacy and safety for paroxetine that was at Methods odds with the data.4 This is problematic because the We reanalysed the data from Study 329 according to the article has been influential in the literature supporting RIAT recommendations. To this end, we used the clini- the use of antidepressants in adolescents.5 cal study report (SKB’s “final clinical report”), including On 14 June 2013, the RIAT researchers asked GSK appendices A-G, which are publically available on the whether it had any intention to restore any of the trials GSK website,9 other publically available documents,10 it sponsored, including Study 329. GSK did not signal and the individual participant data accessed through any intent to publish a corrected version of any of its SAS Solutions OnDemand website,11 on which GSK sub- trials. In later correspondence, GSK stated that the sequently also posted some Study 329 documents (avail- study by Keller and colleagues “accurately reflects the able only to users approved by GSK). After negotiation,12 honestly-held views of the clinical investigator authors” GSK posted about 77 000 pages of de-identified individual and that GSK did “not agree that the article is false, case report forms (appendix H) on that website. We used fraudulent or misleading.”6 a tool for documenting the transformation from regula- Study 329 was a multicentre eight week double blind tory documents to journal publication, based on the CON- randomised controlled trial (acute phase), followed by a SORT 2010 checklist of information to include when six month continuation phase. SKB’s stated primary reporting a randomised trial. The audit record, includ- objective was to examine the efficacy and safety of imip- ing a table of sources of data consulted in preparing ramine and paroxetine compared with placebo in the each part of this paper, is available in appendix 1. treatment of adolescents with unipolar major depres- Except where indicated, in accordance with RIAT http://www.bmj.com/ sion. Secondary objectives were to identify predictors of recommendations, our methods are those set out in the treatment outcomes across clinical subtypes; to provide 1994-96 protocol for Study 329.13 In cases when the meth- ods
Load more

Recommended publications
  • !Hcl^S Office Filed Under Seal
    IN THE UNITED STATES DISTRICT COURT P FOR THE DISTRICT OF MASSACHUSETTS !^D !HCL^S OFFICE Civil Action No. 03-10641-NG-RWZ Civil Action No. 11-10398-NG-RWZ UNITED STATES OF AMERICA, et at, ex rel GREGORY W. THORPE and BLAIR HAMRICK, Plaintiffs, v. SMITH KLINE BEECHAM, INC., and GLAXOSMITHKLINE PLC d/b/a GLAXOSMITHKLINE, Defendants. SEVENTH AMENDED COMPLAINT FILED UNDER SEAL PURSUANT TO 31 U.S.C. §§ 3729 etseq. Matthew J. Fogelman, Esquire FOGELMAN & FOGELMAN LLC 100 Wells Avenue William J. Leonard, pro hac vice Newton, MA 02459 Richard P. Limburg, pro hac vice Kimberly D. Sutton, pro hac vice Brian P. Kenney Alex P. Basilevsky,/>/"6> hac vice M. Tavy Deming OBERMAYER REBMANN MAXWELL & Emily C. Lambert HIPPEL LLP KENNEY & McCAFFERTY, PC One Perm Center, 19th floor 3031 Walton Road, Suite C202 1617 John F. Kennedy Boulevard Plymouth Meeting, PA 19462 Philadelphia, PA 19103 A Homeys for Plaintiffs-Relators Gregory W. Thorpe and Blair Hamrick 4612364 TABLE OF CONTENTS I. BACKGROUND.....................................................................................................2 II. PARTIES ................................................................................................................4 III. JURISDICTION AND VENUE............................................................................6 IV. GENERAL ALLEGATIONS...............................................................................7 A. Drugs Marketed By GSK For Off-Label Use...............................................12 1. Advair ...................................................................................................13
    [Show full text]
  • Sleepless No More SUB.1000.0001.1077
    SUB.1000.0001.1077 2019 Submission - Royal Commission into Victoria's Mental Health System Organisation Name: Sleepless No More SUB.1000.0001.1077 1. What are your suggestions to improve the Victorian community’s understanding of mental illness and reduce stigma and discrimination? Australia is unfortunately a country with pervasive Incorrect Information, Lack of Information, Unsubstantiated Information and Out of Date Information about mental health, emotional health and the underlying reasons for emotional challenges. The reason people do not understand emotional challenges, being promoted as “mental illness”, is that they are not being given full and correct, up to date and relevant information. The Australian public is being given information which is coming from the ‘mental health industry’ not information that reduces mental health problems. The information is industry driven. “Follow the money” is a phrase very relevant in this field. People need to be given correct information that empowers them and ensures that they continue to be emotionally resilient. The information being promoted, marketed as ‘de-stigmatising mental health’ has resulted in people incorrectly self-diagnosing and presenting to their medical professionals asking for help with their anxiety (mental health problem), depression (mental health problem), bipolar (mental health problem), etc. Examples of information and mental health developments I do not see mentioned or promoted in Australia as part of making Australians emotionally resilient, and therefore not diagnosed and medicated as mentally ill: The flaws in the clinical trial process, and how to check the strategies being promoted by health care professionals, the government, doctors and psychiatrists. Making Medicines Safer for All of Us.
    [Show full text]
  • What Influences Healthcare Providers' Prescribing Decisions?
    Research in Social and Administrative Pharmacy xxx (xxxx) xxx Contents lists available at ScienceDirect Research in Social and Administrative Pharmacy journal homepage: www.elsevier.com/locate/rsap What influenceshealthcare providers’ prescribing decisions? Results from a national survey Simani M. Price a,*, Amie C. O’Donoghue b, Lou Rizzo a, Saloni Sapru a, Kathryn J. Aikin b a Westat, Inc., Rockville, MD, USA b U.S. Food and Drug Administration, Silver Spring, MD, USA ARTICLE INFO ABSTRACT Keywords: Background: Prior U.S. Food and Drug Administration (FDA) surveys with healthcare providers (HCPs) have Healthcare providers focused on attitudes toward direct-to-consumer advertising and have not specifically examined professionally- Prescription drug promotion targeted prescription drug promotion. Similarly, there are no recent national surveys of HCPs examining their Detailing interactions with the pharmaceutical industry. Pharmaceutical opinion leaders Objectives: The goal of this study was to use a national sample of HCPs to examine exposure to professionally- Off-label prescribing Prescribers targeted prescription drug promotions and interactions with industry, and knowledge, attitudes and practices related to FDA approval of prescription drugs. Methods: An online national survey was conducted with 2000 HCPs representing primary care physicians (PCPs), specialists (SPs), physician assistants (PAs), and nurse practitioners (NPs). The sample was randomly drawn from WebMD’s Medscape subscriber network, stratified by HCP group, and designed to yield target numbers of completed surveys in each group. Weights were computed to correct for unequal selection probabilities, dif­ ferential response rates, and differential coverage and used to generalize completed surveys to a national pop­ ulation of PCPs, SPs, NPs, and PAs.
    [Show full text]
  • Index 499 Abacavir Case Study, 359 Drug Labeling And, 448 Infectious Diseases And, 317 Pharmacist And, 465 Pharmacodynamics Of
    Index 499 A Allele, 3, 8 detection of, 59, 70-71, 74, 92, 94 Abacavir discrimination, 59, 68, 70-72, 74-75, 88, 90-92, case study, 359 94 drug labeling and, 448 frequency calculations for, 34 infectious diseases and, 317 genetics and, 19, 20, 22, 28-30, 32, 34-47, 49, 52-53 pharmacist and, 465 methodologies, 59, 60, 70-75, 85-94, 96-97 pharmacodynamics of, 198 respiratory diseases and, 327, 336-338, 343, toxicogenomics of, 367 346 ABC transporters, 153-154 -specific amplifications, 92-93 ABCB1, 154-158, 160-161, 258, 263, 314 Allele-specific oligonucleotide (ASO) hybridiza- ABCC transporter family, 161-168 tion, 59, 74, 90-91 Allelic drift, 38 ABCC1, 161-162 All-trans retinoic acid (ATRA), 271 ABCC2, 162-163 Alpha-glucosidase inhibitors, 406, 421-422 ABCC3, 163 gene polymorphisms and, 425 ABCC4, 163 Alzheimer’s disease, 201, 296 ABCC5, 163 American Academy for Study of Liver Diseases, ABCC6, 166 322 American College of Cardiology, 228 ABCC8, 407-409, 410-411, 414, 446 American College of Medical Genetics working ABCC11, 166-167 group, 475 ABCG2, 167-168 American Heart Association Foundation, 228 Acamprosate, 394 American Hospital Formulary Service Drug Infor- Acarbose, 421-422 mation, 461 Americans with Disabilities Act, 479 Access issues, 474 Amino acid, 25 Accreditation Counsel for Pharmacy Education, 461 Amiodarone, 243-244 Accuracy, 72 Amitriptyline, 285 ACE inhibitors, 194-195, 200, 230, 232-233, 296 Analytical specificity, 71-72 Acenocoumarol, 222 Ancillary information, 467-468, 470, 473, 475-477, Acetaminophen, 112 480-481 Anderson,
    [Show full text]
  • Comments to Draft
    March 8, 2021 Institute for Clinical and Economic Review Two Liberty Square, Ninth Floor Boston, MA 02109 Re: Comments to Draft Evidence Report on Anti B-Cell Maturation Antigen CAR T-cell and Antibody Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma Introduction The Alliance for Regenerative Medicine (ARM) appreciates the opportunity to submit the following comments to the Institute for Clinical and Economic Review (ICER) February 11, 2021 draft report on Anti B-Cell Maturation Antigen CAR T-cell and Antibody Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma (“Draft Evidence Report”).1 ARM is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM promotes legislative, regulatory and reimbursement initiatives to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-based therapies. In its 11-year history, ARM has become the global voice of the sector, representing the interests of 380+ members worldwide, including small and large companies, academic research institutions, major medical centers and patient groups. Although focused on one type of rare cancer, the Draft Evidence Report raises important issues for ARM members because of its potential negative impact on the development of the therapies under review and future therapies. ARM is concerned that the timing of the review prevents ICER from taking into account the FDA’s perspective on the appropriate patient population (i.e., through the label), that of expert providers’ perspectives (i.e., through recognized compendia), and the technology’s durability. Consequently, ARM is concerned that the Draft Evidence Report may harm market and patient access.
    [Show full text]
  • Study 329: Trials Why Is It So Important?
    © July - August 2016 RIAT ; Restoring Invisible and Abandoned Study 329: Trials Why is it so important? tudy 329 is a GlaxoSmithKline (GSK) sponsored trial with S22 academic authors that compared paroxetine, imipra- mine, and placebo for adolescent depression. In this trial 275 safetysaafee adolescents with major depression were randomized in a dou- y ble-blind fashion to paroxetine (93), imipramine (95) or pla- cebo (87) for 8 weeks. Those who completed 8 weeks were efficacy studied in a 6-month continuation phase. Published 8-week results (2001)1: Compared with placebo, paroxetine demonstrated significantly greater improvement in The publications report in detail the methods used 3 selected depression rating scales and a Clinical Global Im- to re-analyze Study 329. Notably, they followed the provement score of 1 or 2. The response to imipramine was protocol (and amendments) established by GSK7 not significantly different from placebo for any measure. and used all appropriate procedural steps to avoid Authors’ conclusions: “Paroxetine is generally well tol- bias. They have also made the original anonymous erated and effective for major depression in adolescents.”1 patient data available for others to analyze. This trial has been cited over 600 times and was very influ- RIAT analysis of Study 329 ential in increasing prescribing of paroxetine in this clinical (acute phase) setting.2 The trial protocol7 specified two primary effica- Did these published conclusions reflect cy variables: change in total score on a Hamilton “reality”? depression rating scale (HAM-D) from baseline Critical appraisal of the 2001 publication would have led to endpoint, and the proportion of responders at to questions about the authors’ conclusions.
    [Show full text]
  • Quine and Whitehead: Ontology and Methodology 3
    McHENRY I QUINE AND WHITEHEAD: ONTOLOGY AND METHODOLOGY 3 philosophical scene as of late (e.g., deconstructionism, postmodem relativism), the and Whitehead: Ontology and gulf that separates Whitehead and analytical philosophy is not as great as it used to Quine 'be.3 Before I begin to explore the affinities, as well as some contrasts, between Methodology . Quine and Whitehead, a word of caution is in order. It is well known that Quine wrote his doctoral dissertation, "The Logic of Sequences: A Generalization of LeemonMcHenry Principia Mathematica," under Whitehead's direction.4 Quine also took two of Whitehead's seminars at Harvard,"Science and the Modem World" and "Cosmol­ I LEEMON McHENRY reaches philosophy at Loyola Marymount University, Los ogies Ancient and Modem," but he says that he "responded little to these courses" Angeles, CA 90045, E-mail: [email protected] and "took refuge in his relatively mathematical material on 'extensive abstrac­ tion. "'s Despite Quine's statement that he "retained a vivid sense of being in the presence of the great," he does not acknowledge any philosophical influence from · Introduction . the ph!losoph!es o!'W.V . Qu�e an d Whitehead. Rather, Camap and Russell are cited as the inspirations of Quine's The very idea· of a basis for comparing . , mcluding Qume himself. early development. A.N. Whitehead may be surprising to most philosophe� . philosophy two completely Both produced systems of thought that have taken m When Quine overlapped with Whitehead at Harvard, Whitehead was deeply at the forefron: of c�ntemp�­ involved in working out the details of his metaphysics of process--a philosophic different directions.
    [Show full text]
  • JEMH Vol4 No1 Sept
    ARTICLE SPECIAL THEME ISSUE ARTICLE Privatization of Knowledge and the Creation of Biomedical Conflicts of Interest Leemon B. McHenry Department of Philosophy, California State University, Northridge Jon N. Jureidini Discipline of Psychiatry, University of Adelaide, South Australia rather than to what is meaningful, so that fi ndings that are Abstract likely to be clinical and meaningful are rejected because they fail to reach statistical signifi cance whereas others that appear Scientifi c and ethical misconduct have increased at an clinically trivial are accepted (Ziliak and McCloskey, 2007). Th e alarming rate as a result of the privatization of knowledge. disenchantment with the psychoanalytic paradigm of psychiatry What began as an eff ort to stimulate entrepreneurship led to a massive investment in psychopharmacology and other and increase discovery in biomedical research by physical interventions. A concession now to the limited benefi t strengthening the ties between industry and academics that psychopharmacology off ers would come at great cost to the has led to an erosion of confi dence in the reporting of profession. A vested interest in protecting the new paradigm of research results. Inherent tensions between profi t-directed neurological models of psychiatric disorders reaches beyond the inquiry and knowledge-directed inquiry are instantiated quest for a secure scientifi c foundation. in psychopharmacology, especially in the co-option of academic activity to corporate objectives. The eff ects of To the vulnerability created by personal bias and questionable these tensions are visible in research agendas, publication methodology we must add the dangers of pervasive fi nancial practices, postgraduate education, academic-industry confl icts of interest, of which we investigate the root cause in this partnerships and product promotion.
    [Show full text]
  • Drugs, Money and Misleading Evidence
    Books & arts tallying up the inequalities. She recruited colleagues to gather much more data. The culmination was a landmark 1999 study on gender bias in MIT’s school of science (see go.nature.com/2ngyiyd), which reverber- ated across US higher education and forced many administrators to confront entrenched discrimination. Yet Hopkins would rather have spent that time doing science, she relates. The third story comes from Jane Willenbring, a geoscientist who in 2016 filed a formal com- plaint accusing her PhD adviser, David March- ant, of routinely abusing her during fieldwork in Antarctica years before. Marchant, who has denied the allegations, was sacked from his post at Boston University in April 2019 after an inves- tigation. Picture a Scientist brings Willenbring together with Adam Lewis, who was also a grad- uate student during that Antarctic field season and witnessed many of the events. Their conver- sations are a stark reminder of how quickly and how shockingly the filters that should govern work interactions can drop off, especially in UPRISING, LLC Biologist Nancy Hopkins campaigned for equal treatment at work for female scientists. remote environments. Lewis tells Willenbring he didn’t realize at the time that she had been as they admit on camera. scientists. Its two other protagonists are white bothered, because she did not show it. “A ton The iceberg analogy for sexual harassment is women with their own compelling stories. of feathers is still a ton,” she says. apt. It holds that only a fraction of harassment — Biologist Nancy Hopkins was shocked In stark contrast, the film shows us obvious things such as sexual assault and sex- when Francis Crick once put his hands on Willenbring, now at the Scripps Institution of ual coercion — rises into public consciousness her breasts as she worked in the laboratory.
    [Show full text]
  • In Re: Glaxosmithkline Plc Securities Litigation 05-CV-3751
    UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK __________________________________________ ) In re: GlaxoSmithKline plc Securities ) Civil Action No. 05 CIV. 3751 (LAP) Litigation ) ) DEMAND FOR JURY TRIAL __________________________________________) CONSOLIDATED SECOND AMENDED COMPLAINT JURISDICTION AND VENUE 1. The claims asserted herein arise under §§ 10(b) and 20(a) of the Securities Exchange Act of 1934 (“1934 Act”) and Rule 10b-5. Jurisdiction is conferred by § 27 of the 1934 Act, and 28 U.S.C. §1331. Venue is proper here pursuant to § 27 of the 1934 Act. GlaxoSmithKline plc and SmithKline Beecham Corporation doing business as GlaxoSmithKline plc (collectively “GSK”) is headquartered in London, England, but conducts business in this District. GSK’s ADRs trade on the New York Stock Exchange headquartered in this District. THE PARTIES 2. Lead Plaintiff Joseph J. Masters (“Plaintiff”) acquired publicly traded securities of GSK during the Class Period and was damaged thereby. 3. Defendant GlaxoSmithKline plc is a public company. GlaxoSmithKline plc’s ADRs trade in an efficient market on the NYSE under the symbol “GSK.” GlaxoSmithKline plc’s ordinary shares trade in an efficient market on the London Stock Exchange. Defendant SmithKline Beecham Corporation is a Delaware corporation, which is a wholly-owned subsidiary of GlaxoSmithKline plc. GlaxoSmithKline plc was created in December 2000 when Glaxo Wellcome merged with SmithKline Beecham. Both GlaxoSmithKline plc and SmithKline Beecham, as well as all of their predecessors, subsidiaries and successors, are referred to herein collectively as “GSK.” 4. Defendant Jean-Pierre Garnier (“Garnier”) was CEO and Chairman of GSK throughout the Class Period. By reason of his position, Garnier had access to material inside information about GSK and was able to control directly or indirectly the acts of GSK and the contents of the representations disseminated during the Class Period by or in the name of GSK.
    [Show full text]
  • The American Philosophical Association EASTERN DIVISION ONE HUNDRED TENTH ANNUAL MEETING PROGRAM
    The American Philosophical Association EASTERN DIVISION ONE HUNDRED TENTH ANNUAL MEETING PROGRAM BALTIMORE MARRIOTT WATERFRONT BALTIMORE, MARYLAND DECEMBER 27 – 30, 2013 Important Notices for Meeting Attendees SESSION LOCATIONS Please note: the locations of all individual sessions will be included in the paper program that you will receive when you pick up your registration materials at the meeting. To save on printing costs, the program will be available only online prior to the meeting; with the exception of plenary sessions, the online version does not include session locations. In addition, locations for sessions on the first evening (December 27) will be posted in the registration area. IMPORTANT INFORMATION ABOUT REGISTRATION Please note: it costs $40 less to register in advance than to register at the meeting. The advance registration rates are the same as last year, but the additional cost of registering at the meeting has increased. Online advance registration at www.apaonline.org is available until December 26. 1 Friday Evening, December 27: 6:30–9:30 p.m. FRIDAY, DECEMBER 27 EXECUTIVE COMMITTEE MEETING 1:00–6:00 p.m. REGISTRATION 3:00–10:00 p.m., registration desk (third floor) PLACEMENT INFORMATION Interviewers and candidates: 3:00–10:00 p.m., Dover A and B (third floor) Interview tables: Harborside Ballroom, Salons A, B, and C (fourth floor) FRIDAY EVENING, 6:30–9:30 P.M. MAIN PROGRAM SESSIONS I-A. Symposium: Ancient and Medieval Philosophy of Language THIS SESSION HAS BEEN CANCELLED. I-B. Symposium: German Idealism: Recent Revivals and Contemporary Relevance Chair: Jamie Lindsay (City University of New York–Graduate Center) Speakers: Robert Brandom (University of Pittsburgh) Axel Honneth (Columbia University) Commentator: Sally Sedgwick (University of Illinois–Chicago) I-C.
    [Show full text]
  • Annotated Bibliography of Published Studies Addressing Searching for Unpublished Studies and Obtaining Access to Unpublished Data
    Providing consultancy and research in health economics for the NHS, pharmaceutical and health care industries since 1986 Annotated bibliography of published studies addressing searching for unpublished studies and obtaining access to unpublished data MICK ARBER, Information Specialist MARIA CIKALO, Associate JULIE GLANVILLE, Associate Director CAROL LEFEBVRE, Associate DANIELLE VARLEY, Research Assistant HANNAH WOOD, Information Specialist JUNE 2013 Contents Page No. Acknowledgements Section 1: Introduction 1 1.1 Introduction 1 1.2 Objectives 1 Section 2: Methods 2 2.1 Criteria for considering studies for this Annotated Bibliography 2 2.2 Search methods for identification of studies 3 Section 3: Results 5 3.1 Search results 5 3.2 Structured abstracts 6 Appendices: Appendix A: Search Strategies Appendix B: Papers which we have not been able to obtain and / or assess for relevance All reasonable precautions have been taken by YHEC to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall YHEC be liable for damages arising from its use. Acknowledgements We are grateful to the following individuals and their colleagues, who supplied copies of their publications or information about their publications: Iain Chalmers Kay Dickersin Jini Hetherington Sally Hopewell Chris Hyde Tom Jefferson John Kirwan Steve McDonald David Moher Lorenzo Moja Helen Worthington How to cite this document: Arber M, Cikalo M, Glanville J, Lefebvre C, Varley D, Wood H. Annotated bibliography of published studies addressing searching for unpublished studies and obtaining access to unpublished data.
    [Show full text]